Forging New Paths in Neurodegenerative Drug Development
Mission
Acurex: Bringing critical therapies to patients with age-related neurodegeneration and movement disorders.
Approach
We develop our programs based on evidence from human research, in vivo models, and proprietary cellular systems, which have identified a set of upstream drivers crucial to disease progression. Our programs target these drivers through mechanisms that are druggable, measurable, and clinically translatable.
validation
Acurex’s portfolio of differentiated, late-preclinical assets is built on biology independently validated and supported by external collaborators, peer-reviewed publications, and leading KOLs. Our best-in-class therapeutic programs target clinically proven mechanisms and demonstrate favorable drug-like properties.
strategy
We utilize a partner-first approach to de-risk development and accelerate timelines, ensuring that best-in-class therapies reach patients faster while capturing significant market value.